Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
Roche earns FDA approval for Enspryng in thyroid eye disease, offering the only at-home subcutaneous treatment for TED.
Stocks · News reference
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.